Vanguard Group’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $17.1M | Sell |
|
|||||
|
2024
Q3 | $29.8M | Sell |
|
|||||
|
2024
Q2 | $15.4M | Buy |
|
|||||
|
2024
Q1 | $26.6M | Buy |
|
|||||
|
2023
Q4 | $44.6M | Buy |
|
|||||
|
2023
Q3 | $55M | Buy |
|
|||||
|
2023
Q2 | $118M | Buy |
|
|||||
|
2023
Q1 | $148M | Buy |
|
|||||
|
2022
Q4 | $83M | Buy |
|
|||||
|
2022
Q3 | $116M | Buy |
|
|||||
|
2022
Q2 | $51.2M | Buy |
|
|||||
|
2022
Q1 | $71.1M | Buy |
|
|||||
|
2021
Q4 | $58.8M | Buy |
|
|||||
|
2021
Q3 | $99.9M | Sell |
|
|||||
|
2021
Q2 | $107M | Buy |
|
|||||
|
2021
Q1 | $99M | Buy |
|
|||||
|
2020
Q4 | $91.8M | Buy |
|
|||||
|
2020
Q3 | $79.3M | Buy |
|
|||||
|
2020
Q2 | $70.7M | Buy |
|
|||||
|
2020
Q1 | $39.5M | Buy |
|
|||||
|
2019
Q4 | $41.1M | Buy |
|
|||||
|
2019
Q3 | $27.9M | Sell |
|
|||||
|
2019
Q2 | $29.2M | Buy |
|
|||||
|
2019
Q1 | $33.1M | Buy |
|
|||||
|
2018
Q4 | $35.1M | Buy |
|
|||||
|
2018
Q3 | $37.4M | Buy |
|
|||||
|
2018
Q2 | $40.6M | Buy |
|
|||||
|
2018
Q1 | $40.7M | Buy |
|
|||||
|
2017
Q4 | $44.4M | Buy |
|
|||||
|
2017
Q3 | $28.2M | Buy |
|
|||||
|
2017
Q2 | $24.6M | Buy |
|
|||||
|
2017
Q1 | $18.1M | Buy |
|
|||||
|
2016
Q4 | $17.1M | Buy |
|
|||||
|
2016
Q3 | $13.2M | Buy |
|
|||||
|
2016
Q2 | $10.7M | Buy |
|
|||||
|
2016
Q1 | $12.3M | Buy |
|
|||||
|
2015
Q4 | $22.3M | Buy |
|
|||||
|
2015
Q3 | $14.4M | Buy |
|
|||||
|
2015
Q2 | $14.3M | Buy |
|
|||||
|
2015
Q1 | $8.66M | Buy |
|
|||||
|
2014
Q4 | $6.5M | Buy |
|
|||||
|
2014
Q3 | $6.15M | Buy |
|
|||||
|
2014
Q2 | $7.75M | Buy |
|
|||||
|
2014
Q1 | $4.25M | Buy |
|